Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Poor Quality Sleep
Interventions: Cognitive Behavioral Therapy (CBT); Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 55 Years to 70 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Diabetes Mellitus, Type 1 Diabetes
Interventions: Culturally and linguistically tailored onboarding and support program, Medtronic MiniMed 780G Insulin Pump System; Other · Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 10 Years to 20 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Opioid Use Disorder, Staff, Patients
Interventions: MPACT; Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 1,080 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
Interventions: Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b; Biological
Lead sponsor: AC Immune SA; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 13
States / cities: Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more

Conditions: Overweight and Obesity
Interventions: Financial incentives; Other
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Cancer, Severe Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer, Breast Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Genitourinary Cancer
Interventions: Virtual Cancer and Mental Health Tumor Board; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Danvers, Massachusetts

Conditions: Atopic Dermatitis
Interventions: RPT193, Placebo; Drug
Lead sponsor: RAPT Therapeutics, Inc., a member of the GSK plc group of companies; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 13
States / cities: Anniston, Alabama • Scottsdale, Arizona • San Diego, California + 10 more

Conditions: HIV Infections, Substance Use Disorders, Mental Health Disorder, Addiction, Opioid Use, Drug Use
Interventions: Collaborative Care Model; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Esophageal Achalasia, Esophageal Spasm, Diffuse, Esophageal Motility Disorders
Interventions: peroral endoscopic myotomy, Botulinum toxin injection; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: MF-300 SAD, Placebo, MF-300 Food Effect, MF-300 MAD; Drug
Lead sponsor: Epirium Bio Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Marlton, New Jersey • Austin, Texas

Conditions: Healthy Volunteer
Interventions: Genz-682452, Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma Adult
Interventions: Retifanlimab, Gemcitabine, Docetaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma, Advanced Solid Tumors
Interventions: Ixazomib; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 10
States / cities: Atlanta, Georgia • Peoria, Illinois • Fairway, Kansas + 7 more

Conditions: Dry Eye, Eye Strain, Visual Acuity, Color Perception
Interventions: Gunnar OTC Glasses; Device
Lead sponsor: Pacific University; Other
Eligibility: 18 Years to 42 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Forest Grove, Oregon

Conditions: Type1diabetes, Insulitis, Pancreas Inflamed
Interventions: Definity Suspension for Injection; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV Infections
Interventions: VH4524184, Midazolam, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: Reader Study - Imagio Ultrasound, Reader Study Imagio Ultrasound + Optoacoustic Imaging, Mammography; Device
Lead sponsor: Seno Medical Instruments Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Patellofemoral Pain Syndrome, Patellofemoral Pain
Interventions: Neural Imaging; Other
Lead sponsor: Emory University; Other
Eligibility: 7 Years to 40 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: Flowery Branch, Georgia • Cincinnati, Ohio

Conditions: Healthy
Interventions: LY2409021; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Advanced Cancer
Interventions: BMS-986288, Nivolumab, Regorafenib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 6
States / cities: Costa Mesa, California • Orange, California • Aurora, Colorado + 3 more

Conditions: Haemophilia A, Haemophilia A With Inhibitors
Interventions: Mim8; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 11 more

Conditions: Pneumococcal Infections, Pneumococcal Vaccines
Interventions: V114, Prevnar 13™, RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, MMR II™, VARIVAX™, HIBERIX™; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 42 Days to 90 Days
Enrollment: 1,720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 66
States / cities: Birmingham, Alabama • Dothan, Alabama • Opp, Alabama + 58 more

Conditions: Lupus Erythematosus
Interventions: ABT-199, Placebo; Drug · Other
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 11
States / cities: Clearwater, Florida • DeBary, Florida • Miami, Florida + 7 more

Conditions: Acute Lymphoblastic Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Multigated Acquisition Scan, Positron Emission Tomography, Transplant Conditioning, X-Ray Imaging; Procedure · Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Duarte, California

Search by objective public record fields.

Sleep Well for Healthy Brain

Supporting Medtronic 780G Insulin Pump Adoption in Latino Patients: A Spanish - Language Training Initiative

Methadone Patient Access to Collaborative Treatment

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

Sustaining the Reach of a Scalable Weight Loss Intervention Through Financial Incentives

Adapting the Tumor Board Model for Mental Illness and Cancer

A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

Peer Supported Collaborative Care Mental Health and Substance Use Disorder Care

Peroral Endoscopic Myotomy Versus Botulinum Toxin Injection in Spastic Esophageal Disorders

Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants

Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men

Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment

Effects of Gunnar Computer Glasses on Viewing Comfort and Performance

Pancreas Ultrasound Imaging in type1 Diabetes

A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

Optoacoustic Images Versus Imagio® Ultrasound

Neural Correlates of Knee Sensorimotor Control in Patients With Patellofemoral Pain Syndrome

A Study of LY2409021 Formulations in Healthy Participants

An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia